AKRIKHIN produces effective, affordable and high quality medicines in the most popular therapeutic areas in Russia
The company is in the top 5 leading local pharmaceutical producers by sales on the Russian market showing the significant growth and development rates.
The company’s portfolio includes about 200 products, more than 100 of them are produced at the manufacturing facility in Moscow region.
Our drugs are related to the most essential pharmacotherapeutic groups – tuberculosis, diabetes, dermatology, cardiology, neurology, gynecology, etc. and produced in total compliance with the GMP standards. 45% of products in company’s sales volume are included in the Essential Drugs List.
Akrikhin is one of few Russian producers to have its own Research and Development (R&D) Center. This is a research, analysis and technological center with the very latest technical equipment and analytical instruments. The center’s main focus is generics. Taking into consideration the highly competitive generics market, Akrikhin is concentrated on developing advanced generics and also new forms of known combinations (so called “generic plus” versions). During 2014-2015 within the framework of the import substitution program the company has brought 10 products to the market.
Akrikhin manufacturing facility is a modern complex located on 36 hectares land plot, 20 km from Moscow. The facility comprises of two workshops producing finished pharmaceutical products: solid & semi-solid finished dosage forms. Production volumes are more than 80 mln packs per year. In 2011-2017 the company has realized a largescale investment program of modernization of manufacturing facility with total investments about 50 mln $.
About 1500 people work at Akrikhin, more that 800 of them are based at the manufacturing facility and 500 present company’s field force in 63 regions of Russia.
News from AKRIKHIN
According to the press service of Russia’s Ministry of Health, most of the vaccines required to support the national calendar of preventive vaccinations have already been purchased this year.
“In 2022, the Federal Center for Planning and Organization of Medical Support of the Ministry of Health has already purchased most of the immunobiological medicines to fully support the national calendar of preventive vaccinations, including vaccination against polio, diphtheria, and tetanus,” Interfax quotes the press service of the ministry as saying.
The stocks of pentavalent vaccine and pneumococcal vaccine in the Russian regions are now enough for 4.5 months. If necessary, they will be redistributed among the regions to meet the demand.
“No auctions for the supply of pentavalent vaccine and pneumococcal vaccine are currently announced, including in connection with re-registration of the maximum selling price initiated by the manufacturers of these vaccines,” the Ministry of Health added.
Earlier, the Kommersant newspaper reported that in April and May governmental customers were unable to purchase some foreign vaccines, including those for the prevention of polio, diphtheria, tetanus, and pneumococcal infection. According to the publication, vaccine manufacturers and their Russian partners refused to participate in auctions, since the supply of drugs is unprofitable even at the maximum purchase price due to currency fluctuations and the rising logistics costs.
As it became known earlier, Russia now has prototypes of vaccines against plague and anthrax.
Russia is running out of laboratory tests components. Currently, the country is facing a shortage of reagents for DNA sequencing and analysis from Therma, Agilent, New England Biolabs and Promega, Abbott blood clotting tests, reagents for German DiaSys analyzers (for express testing), BD’s products for qualitative blood tests for bacteria and yeast, and Axygen laboratory plastic. This was reported by Vedomosti.
Aktion Meditsina conducted a survey among employees of public and private clinical and biological laboratories. 63.1% of the participants are not satisfied with the current situation in the market.
49.2% of respondents reported interruptions in supplies, whereas 20% stated that they were no longer receiving them at all. The company also interviewed managers, laboratory doctors, biologists, technologists, laboratory assistants, nursing staff, chief physicians and procurement specialists of medical organizations.
According to 88.5% of respondents, more than half of the equipment used in laboratories is foreign-made. Almost a third of the study participants estimated the share of foreign products in the equipment they use from 70% to 90%, and nearly a half stated that more than 90% is imported.
Among the companies that have ceased supplying the reagents, experts list, among others, Radiometer, Thermo Fisher, Beckman Coulter, and Immucor.
Russia expects to establish new supplies from China, Japan, and South Korea.
As it became known earlier, Russia is probably going to experience a shortage of molecular allergy tests.
The Rosselkhoznadzor has warned participants of the veterinary drugs market about the falsified Eurican DHPPi2-L vaccine that may appear in the Russian market.
“The original drug of the L414454 series (manufactured by Boehringer Ingelheim Animal Health France SCS, France) has an expiry date on March 10, 2016. The sticker label of the surrogate has a design that is different from the original product, with the expiry dates for the L414454 series indicated as December 10, 2021, January 13, 2022, December 10, 2023, and January 13, 2024,” the message published on the Rosselkhoznadzor’s official website says.
All cases of detection of Eurican DHPPi2-L vaccine with the above signs of falsification must be reported to Rosselkhoznadzor, the agency stressed.
In the early May, it became known that the Moscow Endocrine Plant is ready to produce veterinary anesthetics.
The Council of the Eurasian Economic Commission (EEC) has approved a new edition of the Rules of good pharmacovigilance practice (GVP) of the Eurasian Economic Union (EAEU). This is reported on the official website of the EEC.
“There are now detailed specifications of the pharmacovigilance processes for which the manufacturer of medicines is responsible. The possibilities of interaction between the manufacturer and the authorized bodies have been expanded. There are now more possibilities for using methods of active safety monitoring, as well as the use of labeling of unsafe medicines with special warning signs,” the report says.
The new edition takes into account the experience of pharmacovigilance of the EAEU countries and the best international approaches, the Eurasian Economic Commission stressed.
“The EEC Council has also made changes to the requirements for the instructions (package leaflet) on the use of human medicines. It is stipulated that it will include information with a warning about the safety of drugs obtained by human blood plasma processing. The document outlines unified approaches of drug manufacturers of the Eurasian Economic Union to the indication of special warnings about the security measures taken in relation to viral transmission with blood products. This will avoid possible differences in the examination of the text of the general characteristics of the medicinal product and the package leaflet for such medicines in the EAEU countries,” the EEC added.
As it became known earlier, early access to “breakthrough” drugs has become possible in the territory of the EAEU.